

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:
Thomas Kodadek

Serial No.: 10/754,457

Filed: January 9, 2004

For: METHODS AND COMPOSITIONS
COMPRISING CAPTURE AGENTS

Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSD:935US

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

June 30, 2004

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT**MS AMENDMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:935US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 30, 2004

**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 30, 2004

**CERTIFICATE OF MAILING
37 C.F.R. 1.8**

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

June 30, 2004

Date

Steven L. Highlander

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/754,457 entitled "METHODS AND COMPOSITIONS COMPRISING CAPTURE AGENTS" – Thomas Kodadek*
Our reference: UTSD:935US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A13, B1-B9 and C1-C27.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSD:935US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/kmv
Encl.: as noted



Form PTO-1449 (modified)		Atty. Docket No. UTSD:935US	Serial No. 10/754,457
List of Patents and Publications for Applicant's		Applicant Thomas Kodadek	
INFORMATION DISCLOSURE STATEMENT		Filing Date: January 9, 2004	Group: 1645
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 2</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0006620	1/17/02	Short	435	6	4/03/01
	A2	2002/0022227	2/21/02	Short	435	6	4/12/01
	A3	2002/0098493	7/25/02	Nathan	435	6	5/25/01
	A4	2002/0137106	9/26/02	Leung and Lomas	435	7.9	3/07/02
	A5	4,789,628	12/06/88	Nayak	435	7	6/16/86
	A6	5,149,626	9/22/92	Fleming	435	7.9	12/18/89
	A7	6,297,059	10/02/01	Song and Swanson	436	501	6/22/99
	A8	6,306,643	10/23/01	Galtalen and Chee	435	287.2	8/24/98
	A9	6,344,330	2/05/02	Ellman and Choong	435	7.1	3/27/98
	A10	6,344,334	2/05/02	Ellman and Choong	435	7.1	3/26/99
	A11	6,365,418	4/02/02	Wagner <i>et al.</i>	436	518	5/18/00
	A12	6,406,921	6/18/02	Wagner <i>et al.</i>	436	518	7/14/98
	A13	6,465,183	10/15/02	Wolber	435	6	7/01/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	0268296	5/25/88	Europe			English
	B2	0317804	5/31/89	Europe			English
	B3	0491362	6/24/92	Europe			Abstract
	B4	0586618	7/16/97	Europe			English
	B5	0818467	1/14/98	Europe			English
	B6	WO 01/69258	9/20/01	PCT			English
	B7	WO 02/31510	4/18/02	PCT			English

25391809.1

EXAMINER: /Ann Lam/	DATE CONSIDERED: 02/09/2010
---------------------	-----------------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:935US

10/754,457

List of Patents and Publications for Applicant's

Applicant

Thomas Kodadek

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 9, 2004

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B8	WO 02/063299	8/15/02	PCT			English
	B9	WO 03/074990	9/12/03	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bachhawat-Sikder and Kodadek, "Mixed-element capture agents: a simple strategy for the construction of synthetic, high-affinity protein capture ligands," <i>J. Am. Chem. Soc.</i> , 125:9550-9551, 2003.
	C2	Burkoth <i>et al.</i> , "Toward the synthesis of artificial proteins: the discovery of an amphiphilic helical peptoid assembly," <i>Chem. Biol.</i> , 9:647-654, 2002.
	C3	Cussac <i>et al.</i> , "A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity," <i>FASEB J.</i> , 13:31-38, 1999.
	C4	Fancy and Kodadek, "Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light," <i>Proc. Natl. Acad. Sci., USA</i> , 96:6020-6024, 1999.
	C5	Figliozzi <i>et al.</i> , "Synthesis of N-substituted glycine peptoid libraries," <i>Methods Enzymol.</i> , 267:437-447, 1996.
	C6	Hajkuk <i>et al.</i> , "Discovering high-affinity ligands for proteins," <i>Science</i> , 278(5337):497-499, 1997.
	C7	Han and Kodadek, "Peptides selected to bind the Gal80 repressor are potent transcriptional activation domains in yeast," <i>J. Biol. Chem.</i> , 275(20):14979-14984, 2000.
	C8	Kiessling <i>et al.</i> , "Synthetic multivalent ligands in the exploration of cell-surface interactions," <i>Curr. Opin. Chem. Biol.</i> , 4:696-703, 2000.
	C9	Kirshenbaum <i>et al.</i> , "Sequence-specific polypeptides: a diverse family of heteropolymers with stable secondary structure," <i>Proc. Natl. Acad. Sci., USA</i> , 95:4303-4308, 1998.
	C10	Kitov <i>et al.</i> , "Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands," <i>Nature</i> , 403:669-672, 2000.

25391809.1

EXAMINER: /Ann Lam/

DATE CONSIDERED: 02/09/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:935US

10/754,457

List of Patents and Publications for Applicant's

Applicant

Thomas Kodadek

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 9, 2004

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11/	Kodadek, "Protein microarrays: prospects and problems," <i>Chem. Biol.</i> , 8:105-115, 2001.
	C12/	Kodadek, "Development of protein-detecting microarrays and related devices," <i>Trends Biochem. Sci.</i> , 27(6):295-300, 2002.
	C13/	Koehler <i>et al.</i> , "Discovery of an inhibitor of a transcription factor using small molecule microarrays and diversity-oriented synthesis," <i>J. Amer. Chem. Soc.</i> , 125:8420-8421, 2003.
	C14/	Kuruvilla <i>et al.</i> , "Dissecting glucose signaling with diversity-oriented synthesis and small-molecule microarrays," <i>Nature</i> , 416:653-657, 2002.
	C15/	Ladbury <i>et al.</i> , "Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal," <i>Proc. Natl. Acad. Sci., USA</i> , 92:3199-3203, 1995.
	C16/	Maly <i>et al.</i> , "Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors," <i>Proc. Natl. Acad. Sci., USA</i> , 97:2419-2424, 2000.
	C17/	Melcher and Xu, <i>EMBO J.</i> , "Gal80-Gal80 interaction on adjacent Gal4p binding sites is required for complete GAL gene repression," 20:841-851, 2001.
	C18/	Merritt <i>et al.</i> , "Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin," <i>J. Amer. Chem. Soc.</i> , 124:8818-8824, 2002.
	C19/	Olejniczak <i>et al.</i> , "Stromelysin inhibitors designed from weakly bound fragments: effects of linking and cooperativity," <i>J. Amer. Chem. Soc.</i> , 119:5828-5832, 1997.
	C20/	Oliver <i>et al.</i> , "Multiplexed Analysis of Human Cytokines by Use of the FlowMetric System," <i>Clinical Chemistry</i> , 44:2057-2060, 1998.
	C21/	Schreiber, "Target-oriented and diversity-oriented organic synthesis in drug discovery," <i>Science</i> , 287(5460), 1964-1969, 2000.
	C22/	Shuker <i>et al.</i> , "Discovering high-affinity ligands for proteins: SAR by NMR," <i>Science</i> , 274:1531-1534, 1996.
	C23/	Stoll <i>et al.</i> , "Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53," <i>Biochemistry</i> , 40:336-344, 2001.
	C24/	Terskikh <i>et al.</i> , "'Peptabody': a new type of high avidity binding protein," <i>Proc. Natl. Acad. Sci., USA</i> , 94:1663-1668, 1997.

25391809.1

EXAMINER: /Ann Lam/

DATE CONSIDERED: 02/09/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:935US

10/754,457

List of Patents and Publications for Applicant's

Applicant

Thomas Kodadek

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 9, 2004

Group:

1645

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Thoma <i>et al.</i> , "Nanomolar E-selectin inhibitors: 700-fold potentiation of affinity by multivalent ligand presentation," <i>J. Amer. Chem. Soc.</i> , 123:10113-10114, 2001.
	C26	Vignali, "Multiplexed particle-based flow cytometric assays," <i>J. of Immunol. Methods</i> , 243:243-255, 2000.
	C27	Woodbury and Vinton, "Methods of screening combinatorial libraries using immobilized or restrained receptors," <i>J. Chromatogr B Biomed. Sci. Appl.</i> , 725:113-137, 1999.

25391809.1

EXAMINER:

/Ann Lam/

DATE CONSIDERED:

02/09/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./